Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CGEN

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Compugen

CGEN
Current price
1.76 USD +0.02 USD (+1.15%)
Last closed 1.74 USD
Company cgen.com
ISIN IL0010852080
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 164 582 880 USD
Yield for 12 month +2.92 %
1Y
3Y
5Y
10Y
15Y
CGEN
21.11.2021 - 28.11.2021

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. Address: Azrieli Center, Holon, Israel, 5885849

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.50 USD

P/E Ratio

Dividend Yield

Financials CGEN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+27 864 000 USD

Last Year

+33 459 000 USD

Current Quarter

+2 284 000 USD

Last Quarter

+1 471 000 USD

Current Year

+19 934 000 USD

Last Year

+31 455 000 USD

Current Quarter

-116 000 USD

Last Quarter

+796 000 USD
EBITDA -14 305 500 USD
Operating Margin TTM -367.56 %
Price to Earnings
Return On Assets TTM -8.07 %
PEG Ratio
Return On Equity TTM -24.22 %
Wall Street Target Price 5.50 USD
Revenue TTM 27 589 000 USD
Book Value 0.62 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -10.70 %
Dividend Yield
Gross Profit TTM 19 361 000 USD
Earnings per share -0.16 USD
Diluted Eps TTM -0.16 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -51.27 %

Stock Valuation CGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.15
Price Sales TTM 5.97
Enterprise Value EBITDA -19.16
Price Book MRQ 2.85

Technical Indicators CGEN

For 52 Weeks

1.13 USD 2.66 USD
50 Day MA 1.54 USD
Shares Short Prior Month 1 471 262
200 Day MA 1.69 USD
Short Ratio 5.07
Shares Short 1 462 026
Short Percent 1.62 %